Skip to content
To the full analysis

Pediatrix Medical Group stock: balance sheet and debt

MD
$31.40Closing price of 12 Nov 2026MEQIRI Score 70 out of 100

Pediatrix Medical Group has a debt to equity ratio of 0.76 and an interest coverage of 7x.

Daily figure as of 13 Nov 2026

Debt / Equity
0.76
Interest coverage
7x
Current ratio
1.66
Cash & equivalents
$499.72M
Total assets
$2.25B
Equity ratio
38.5%
Goodwill
$1.26B
Plus intangible assets of $16.86M
Net debt
$160.58M

Total assets and equity ratio

How large the balance sheet of Pediatrix Medical Group, Inc. is, how much of it is equity and how much is goodwill from acquisitions.

Equity ratio

Figures as a table
YearTotal assetsGoodwill and intangible assetsof which goodwillEquity ratioNet debt
2006$1.14B$777.48M$770.29M76.3%−$134.4M
2007$1.3B$870.36M$858.92M73.6%−$119.96M
2008$1.5B$1.13B$1.13B64.5%$105M
2009$1.69B$1.27B$1.27B70.4%$18.56M
2010$2.04B$1.6B$1.6B71.0%$103.05M
2011$2.27B$1.75B$1.75B76.2%$6.74M
2012$2.75B$2.26B$2.17B74.0%$116.47M
2013$3.05B$2.5B$2.39B76.8%−$10.36M
2014$3.61B$2.97B$2.78B62.8%$515.36M
2015$4.55B$3.79B$3.37B53.6%$1.21B
2016$5.34B$4.75B$4.08B51.7%$1.64B
2017$5.87B$5.24B$4.6B52.3%$1.78B
2018$5.93B$5.28B$4.69B52.0%$1.92B
2019$4.15B$1.51B$1.48B36.2%$1.61B
2020$3.35B$1.5B$1.48B22.3%$575.97M
2021$2.72B$1.53B$1.51B32.9%$578.72M
2022$2.35B$1.55B$1.53B38.0%$614.02M
2023$2.22B$1.41B$1.38B38.2%$523.91M
2024$2.15B$1.25B$1.24B35.5%$313.81M
2025$2.25B$1.28B$1.26B38.5%$160.58M

The equity ratio divides total equity, including non-controlling interests, by total assets. Net debt is debt minus cash and short-term investments; a negative figure means cash exceeds debt.

Equity and debt

What the company owns and owes

  • Cash & equivalents
  • Equity
  • Debt
Figures as a table
YearCash & equivalentsEquityDebtDebt / Equity
2006$135.26M$865.8M$860K0
2007$120.89M$959.05M$924K0
2008$35.11M$965.14M$140.11M0.15
2009$31.88M$1.19B$50.44M0.04
2010$43.63M$1.45B$146.68M0.1
2011$22.74M$1.73B$29.47M0.02
2012$27.86M$2.04B$144.33M0.07
2013$37.59M$2.34B$27.24M0.01
2014$53.96M$2.27B$569.32M0.25
2015$60.43M$2.44B$1.27B0.52
2016$66.98M$2.76B$1.71B0.62
2017$70.49M$3.07B$1.85B0.6
2018$58.67M$3.09B$1.97B0.64
2019$182.38M$1.5B$1.79B1.2
2020$1.23B$747.49M$1.8B2.41
2021$487.11M$896.49M$1.07B1.19
2022$103.06M$891.63M$717.08M0.8
2023$177.74M$849.06M$701.65M0.83
2024$348.51M$764.94M$662.31M0.87
2025$499.72M$865.85M$660.3M0.76

Data status and sources

Score
Daily value of 13 Nov 2026, recalculated nightly
Price
Closing price of 12 Nov 2026
Latest annual report
Fiscal year 2025, period end 31 Dec 2025
Source
Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.

Mandatory disclosures for this rating

  • ; time horizon around 12 months
  • Rated Strong since 7 Nov 2026, previously Neutral
  • Valuation signal Undervalued since 7 Nov 2026
  • End-of-day prices, metrics cached for up to 24 hours
  • Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
  • Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
  • Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.

MEQIRI counts visits without cookies. With your consent we remember for 90 days where you came from, also in your account, count page changes and time on page, recognise your next visit and load the Meta Pixel, which measures our advertising. You can withdraw your consent at any time under Cookie settings. Privacy